Drug Profile


Alternative Names: Aripazine; PER 977

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator Perosphere
  • Class Amides; Coagulants; Piperazines; Small molecules
  • Mechanism of Action Blood coagulation factor modulators; Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Haemorrhage

Most Recent Events

  • 04 Oct 2016 Phase-II development is ongoing in USA (Perosphere pipeline, October 2016)
  • 02 Apr 2015 Ciraparantag receives Fast Track designation for Haemorrhage [IV] (In volunteers) in USA
  • 05 Nov 2014 Efficacy and adverse events data from a phase I/II trial in Haemorrhage released by Perosphere
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top